Drug Information

Drug (ID: DG02012) and It's Reported Resistant Information

• Name: H-mMnO2
• Indication:
  In total 1 Indication(s)
  . .; .

Type(s) of Resistant Mechanism of This Drug

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Kidney cancer [ICD-11: 2C90]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) [1]

• Metabolic Type: Mitochondrial metabolism
• Sensitive Disease: Clear cell renal cell carcinoma [ICD-11: 2C90.Y]
• Molecule Alteration: Expression; Up-regulation

Differential expression of the molecule in resistant disease

• Classification of Disease: Kidney cancer [ICD-11: 2C90]
• The Specified Disease: Clear cell renal cell carcinoma
• The Studied Tissue: Kidney
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 1.76E-14; Fold-change: 5.67E-01; Z-score: 8.53E+00
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Caki1/R cells; Liver; Homo sapiens (Human); CVCL_0234
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: CD276 and MTHFD2 were identified as a potential surface marker and a therapeutic target, respectively, for targeting sunitinib-resistant ccRCC and its CSC population. MTHFD2 knockdown remodeled the folate-nucleotide metabolism of tumor cells. Moreover, H-mMnO7was confirmed to be able of altering GABA metabolism by enhancing GABA catabolism in drug-resistant tumor cells.

Key Molecule: Cluster of differentiation 276 (CD276) [1]

• Metabolic Type: Nucleic acid metabolism
• Sensitive Disease: Clear cell renal cell carcinoma [ICD-11: 2C90.Y]
• Molecule Alteration: Expression; Up-regulation

Differential expression of the molecule in resistant disease

• Classification of Disease: Kidney cancer [ICD-11: 2C90]
• The Specified Disease: Clear cell renal cell carcinoma
• The Studied Tissue: Kidney
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 1.12E-50; Fold-change: 8.24E-01; Z-score: 2.07E+01
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: 786O/R cells; Liver; Homo sapiens (Human); CVCL_1051
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: CD276 and MTHFD2 were identified as a potential surface marker and a therapeutic target, respectively, for targeting sunitinib-resistant ccRCC and its CSC population. MTHFD2 knockdown remodeled the folate-nucleotide metabolism of tumor cells. Moreover, H-mMnO6was confirmed to be able of altering GABA metabolism by enhancing GABA catabolism in drug-resistant tumor cells.

References

• Ref 1: Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and gamma-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma. ACS Nano. 2024 Oct 8;18(40):27487-27502.